Ciara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Cargo Therapeutics CRGX, , a clinical-stage biotech specializing in cancer treatments, set terms for its initial public offering early Monday with plans to offer 18.8 million shares priced at $15 to $17 each. The company would raise $319.6 million at the top of that range at a valuation of $656.2 million. JP Morgan, Jefferies, TD Cowen and Truist Securities are underwriting the deal.
Proceeds will be used to fund clinical development, R&D and for working capital and other general corporate purposes. The company is pre-revenue and loss-making, as is often the case for biotechs with no approved drugs. The company has applied to list on Nasdaq under the ticker “CRGX.” The Renaissance IPO ETF IPO, +3.35% has gained 29% in the year to date, while the S&P 500 SPX, +0.94% has gained 13.5%.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
A Shopper Says This $15 Oil Tightens Their “Droopy Neck” and “Visibly Reduces” WrinklesRadha Beauty’s Rosehip Oil is 25 percent off and has more than 14,000 five-star ratings. Shop the skin-tightening and scar-reducing oil on Amazon for $15.
Read more »
Google ditches plans for $15 billion in Bay Area developmentGoogle has abandoned its plans for $15 billion’s worth of affordable housing, office and retail development in Silicon Valley.
Read more »
34 Pretty Trinkets To Buy Yourself Just BecauseHmm, would you look at the time, it's 'buy myself this cult-fave $15 ring for no reason o'clock.'
Read more »
15 full-size SUVs with the most cargo spaceIf you got stuff and more stuff, this list is for you
Read more »